Source-grounded facts extracted from LIPELLA PHARMACEUTICALS INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
LIPELLA PHARMACEUTICALS INC. entered chapter 11 in United States Bankruptcy Court for the Western District of Pennsylvania.
“On [Filing Date] , [Company Name, Inc.] (the “Company”) and certain of its subsidiaries (collectively, the “Debtors”) filed voluntary petitions for relief under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Western District of Pennsylvania (the “Bankruptcy Court”).”
LIPELLA PHARMACEUTICALS INC. received a nasdaq delisting notice notice regarding other (rules 5100, 5635(d), 5640).
“June 17, 2025, indicating that the Panel has determined to delist the Company’s common stock, par value $0.0001 per share (the “Common Stock”), from the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5100, which permits Nasdaq to use its discretionary authority for public interest concerns, due to the Company’s non-compliance with (i) Nasdaq Listing Rule 5635(d), which requires prior shareholder approval for the issuance, other than in a public offering, of 20% or more of a company’s outstanding shares at a per share price less than the Minimum Price (as defined in such rule), and (ii)”
LIPELLA PHARMACEUTICALS INC. received a nasdaq noncompliance notice notice regarding other (rules 5635(d), 5640).
“on to its investment bank for placement agent and related consulting and advisory services received in connection with the Company’s private placement transactions conducted between December 2024 and March 2025, the Staff has determined that the Company failed to comply with (i) Nasdaq Listing Rule 5635(d), which requires prior shareholder approval for the issuance, other than in a public offering, of 20% or more of a company’s outstanding shares at a per share price less than the Minimum Price (as defined in Nasdaq Listing Rule 5635(d)(1)(A)) (the “Shareholder Approval Rule”) and (ii) Nasdaq”
LIPELLA PHARMACEUTICALS INC.: Increased the number of designated Series C Voting Convertible Preferred Stock shares from 1,050,000 to 1,260,000 (effective 2025-04-08).
“On April 8, 2025, the Company filed a Certificate of Amendment of Certificate of Designation of Preferences, Rights and Limitations of Series C Voting Convertible Preferred Stock (the “Series C Certificate of Amendment”) with the Secretary of State of the State of Delaware. The Series C Certificate of Amendment amended the Certificate of Designation of Preferences, Rights and Limitations of Series C Voting Convertible Preferred Stock of the Company (the “Certificate of Designation”) to increase the number of shares of the Company’s Series C Voting Convertible Preferred Stock, par value $0.0001 per share, designated pursuant to the Certificate of Designation from 1,050,000 shares to 1,260,000 shares.”
LIPELLA PHARMACEUTICALS INC. received a nasdaq hearing update notice regarding stockholders equity (rules 5550(b)(1)).
“January 10, 2025, Lipella Pharmaceuticals Inc. (the “Company”) received a decision (the “January Letter”) from the Nasdaq Hearings Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company’s request for continued listing on the Nasdaq Capital Market, subject to the Company demonstrating compliance with Nasdaq Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Requirement”), including the achievement of interim milestones. Specifically, the Panel granted the Company’s request for continued listing, subject to the following: (i) on or before April 14, 2025, the C”
LIPELLA PHARMACEUTICALS INC. received a nasdaq hearing update notice regarding stockholders equity (rules 5550(b)(1), 5550(a)(2)).
“January 10, 2025, Lipella Pharmaceuticals Inc. (the “Company”) received a decision (the “January Letter”) from the Nasdaq Hearings Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company’s requ”
LIPELLA PHARMACEUTICALS INC.: Filed Series B Certificate of Designation and Certificate of Correction, and Series C Certificate of Designation, establishing series preferred stock rights and preferences (effective 2024-12-20).
“On December 23, 2024, the Company filed the Series C Certificate of Designation with the Delaware Secretary of State, establishing the rights, preferences, privileges, qualifications, restrictions, and limitations relating to the Series C Preferred Stock.”
LIPELLA PHARMACEUTICALS INC.: effected a one-for-eight reverse stock split of common stock (effective 2024-11-07).
“On November 7, 2024, Lipella Pharmaceuticals Inc. (the “Company”), acting pursuant to authority received at an annual meeting of its stockholders on September 10, 2024, filed with the Secretary of State of the State of Delaware a certificate of amendment (the “Charter Amendment”) to its second amended and restated certificate of incorporation, as amended (the “Certificate of Incorporation”), which effected a one-for-eight reverse stock split (the “Reverse Stock Split”) of all of the Company’s outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).”
LIPELLA PHARMACEUTICALS INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“April 17, 2024, Lipella Pharmaceuticals Inc. (the “Company”) received a letter (the “Nasdaq Letter”) from the Nasdaq Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for the last 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share of its Common Stock, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasdaq Let”
LIPELLA PHARMACEUTICALS INC.: Eliminated and canceled all designations, rights, preferences and limitations of Series A Preferred Stock (effective 2024-04-11).
“On April 11, 2024, the Company filed an Elimination of Certificate of Designation of the Preferences, Rights and Limitations of Series A Preferred Stock (the “Series A Elimination Certificate”) with the Secretary of State of the State of Delaware, in order to eliminate and cancel all designations, rights, preferences and limitations of the shares of the Company’s Series A convertible preferred stock, par value $0.0001 per share (the “Series A Preferred Stock”).”
LIPELLA PHARMACEUTICALS INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“November 21, 2023, Lipella Pharmaceuticals Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company may have failed to maintain a required minimum of $2,500,000 in stockholders’ equity for continued listing, as required under Nasdaq Listing Rule 5550(b)(1) (the “Minimum Equity Rule”), based on the financial results reported in the Company’s Form 10-Q for the period ended September 30, 2023, as filed with the SEC on November 14, 2023. The Notice has no immediate effect on the listing of the Company’s common stock, par value $0.0001 per sha”
LIPELLA PHARMACEUTICALS INC. shareholders approved Ratification of Urish Popeck & Co., LLC as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-11-21 meeting.
“The appointment of Urish Popeck & Co., LLC as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023, was ratified”
LIPELLA PHARMACEUTICALS INC. shareholders approved Amendment of 2020 Stock Incentive Plan to increase authorized shares by 1,000,000 at the 2023-11-21 meeting.
“esults with respect to the election of each such nominee were as follows: Nominee For Withheld Broker Non-Votes Jonathan Kaufman 2,237,280 21,582 184,927 Michael Chancellor 2,232,180 26,682 184,927 Lori Birder 2,234,742 24,120 184,927 Daniel Cohen 2,234,742 24,120 184,927 Byong (Christopher) Kim 2,220,122 38,740 184,927 Ryan Pruchnic 2,234,842 24,020 184,927 Naoki Yoshimura 2,222,722 36,140 184,927 Proposal 2 – The”
LIPELLA PHARMACEUTICALS INC. shareholders approved Election of seven director nominees at the 2023-11-21 meeting.
“The seven (7) director nominees named in the Proxy Statement were elected by a plurality of the votes cast by holders of the shares present and entitled to vote at the Annual Meeting”
LIPELLA PHARMACEUTICALS INC. entered into New Lease with Bridgeway Development Corporation valued at approximately $27,600 (effective 2023-07-27).
“On July 27, 2023, Lipella Pharmaceuticals Inc. (the “Company”) entered into a new lease agreement (the “New Lease”) with Bridgeway Development Corporation for the lease of approximately 3,275 square feet of space in the building located at 7800 Susquehanna Street, Pittsburg, PA 15208 (the “Premises”).”
Dr. Lori Birder was appointed as Director at LIPELLA PHARMACEUTICALS INC..
“Effective June 17, 2023, the board of directors (the “Board”) of Lipella Pharmaceuticals Inc., a Delaware corporation (the “Company”), pursuant to its powers under the Company’s second amended and restated by-laws, appointed Dr. Lori Birder as a member of the Board.”
David Battleman resigned as Director at LIPELLA PHARMACEUTICALS INC..
“On May 30, 2023, Dr. David Battleman informed the board of directors, or the Board, of Lipella Pharmaceuticals Inc. (the “Company”) that he will resign from the Board, effective June 17, 2023.”
LIPELLA PHARMACEUTICALS INC. reported quarter ended March 31, 2023 results: net income approximately $1.1 million.
“Net loss for the quarter ended March 31, 2023 was approximately $1.1 million.”
LIPELLA PHARMACEUTICALS INC. reported financial results for the fiscal year ended December 31, 2022.
“today provided a business update and reported financial results for the year ended December 31, 2022.”
Daniel Cohen was appointed as Director at LIPELLA PHARMACEUTICALS INC..
“On March 21, 2023, the board of directors (the “Board”) of Lipella Pharmaceuticals Inc., a Delaware corporation (the “Company”), pursuant to its powers under the Company’s second amended and restated by-laws, appointed Daniel Cohen as a member of the Board, thereby increasing the Board membership count to seven (7).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.